An acute pharmacological intervention introduced novel ROMK inhibitors, compound A, MK-7145, and MK-8153 [182,183], thereby reducing ROMK activity and therefore ablating the function of coupled sodium reabsorption by NKCC2 and ENaC, which has been proved to be a novel therapeutic pathway for hypertension. Here, SLC12A1 is linked to hypertensive disorder.